Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31306342 | 0.80 | ALDH1A1 (0.41) | CYP11B2CREBBPBRD4PDE2AHIF1A | |
| SCHEMBL14996666 | 0.80 | PDE2A (0.41) | CYP11B2CREBBPBRD4PDE2AHIF1A | |
| SCHEMBL15745980 | 0.78 | BRAF (0.47) | CYP11B2 | |
| SCHEMBL21051439 | 0.77 | NPC1 (0.42) | CREBBPBRD4MAPT | |
| SCHEMBL27037461 | 0.77 | PDE2A (0.43) | CYP11B2CREBBPBRD4PDE2AMAPT | |
| SCHEMBL9911757 | 0.76 | PTGS2 (0.46) | CREBBPBRD4PDE2AHIF1AMAPT | |
| SCHEMBL14996605 | 0.74 | PDE2A (0.45) | PDE2AMAPT | |
| SCHEMBL14996624 | 0.74 | ALDH1A1 (0.41) | CREBBPBRD4PDE2A | |
| SCHEMBL14996574 | 0.72 | PDE2A (0.48) | CYP1A2PDE2A | |
| SCHEMBL25615539 | 0.71 | ADRB2 (0.37) | CYP11B2CREBBPBRD4PDE2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9790203-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | CYP1A1 9/4885CYP1A2 8/4885CYP1B1 11/4885 |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | CYP1A1 8/4885CYP1A2 10/4885CYP1B1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.